COMMUNIQUÉS West-GlobeNewswire

AIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point
03/08/2026
Milestone Advances Ampligen® Toward Key Clinical Benefit Readout in December 2026 and Overall Survival Analysis in Mid-2027 OCALA, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” [...]
SRX Global Portfolio Company Smartkem, Inc. (NASDAQ: SMTK) Announces Merger
03/08/2026
NORTH PALM BEACH, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company”, or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments [...]
Codexis Appoints David Butler, PhD, to Strategic Advisory Board
03/08/2026
REDWOOD CITY, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, today [...]
Vaso Corporation Completes Sale of NetWolves Network Services to COEO Solutions
03/08/2026
Vaso Corporation 137 Commercial Street Plainview, New York 11803 Tel: (516) 997-4600 Fax: (516) 997-2299 Investor Contact: Jonathan Newton Investor Relations Phone: 516-997-4600 Email: jnewton@vasocorporation.com [...]
SBC Medical to Announce 2Q 2026 Financial Results
03/08/2026
IRVINE, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization providing management support across a wide range [...]
Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance
03/08/2026
WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics, Inc. (“GPCR [...]
Felix Ankel, MD, Elected President of ABEM
03/08/2026
American Board of Emergency Medicine Announces 2026-2027 Executive Committee EAST LANSING, Mich., Aug. 03, 2026 (GLOBE NEWSWIRE) -- The American Board of Emergency Medicine (ABEM) announces the election of Felix Ankel, [...]
The Ferrari Foundation Advances Fifth Annual Adam Ferrari Health Science Scholarship to Finalist Review
03/08/2026
Three finalists will be selected for the $20,000 scholarship before the recipient is announced on September 1 IRVINE, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- The Ferrari Foundation has begun the finalist selection [...]
BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer
03/08/2026
Mainz, Germany, August 3, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that its Supervisory Board has appointed Guido Oelkers, Ph.D., to the Management Board as Chief [...]
Leo International Precision Health AG: Mr Leo Wang, Allocation of 78,844,000 bonus shares pursuant to the capital increase from the company’s own funds, which was resolved at the issuer’s Annual General Meeting on 12 June 2026 and...
03/08/2026
Leo International Precision Health AG: Mr Leo Wang, Allocation of 78,844,000 bonus shares pursuant to the capital increase from the company’s own funds, which was resolved at the issuer’s Annual General Meeting on 12 [...]
Leo International Precision Health AG: PC Beteiligungsgesellschaft mbH, Allocation of 3.772.368 bonus shares pursuant to the capital increase from the company’s own funds, which was resolved at the issuer’s Annual General Meeting on 12...
03/08/2026
Leo International Precision Health AG: PC Beteiligungsgesellschaft mbH, Allocation of 3.772.368 bonus shares pursuant to the capital increase from the company’s own funds, which was resolved at the issuer’s Annual [...]
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
03/08/2026
Combines highly complementary businesses, with a diversified portfolio of CNS medicines totaling approximately $2.2 billion in combined annual revenues Enhanced financial position and free cash flow generation enabling [...]
Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
03/08/2026
• Q2’26 Total Net Revenue of $ 343 Million, Up 14% YoY • Record Quarterly Total SUBLOCADE® Net Revenue of $ 253 Million in Q2'26, Up 21% YoY • Record Quarterly GAAP Net Income of $122 Million and Record Non-GAAP Net [...]
Supernus Announces Second Quarter 2026 Financial Results
03/08/2026
Total revenues were $219.1 million in the second quarter 2026, a 32% increase compared to same period last year. Combined revenues of the Company's four growth products increased to $175.7 million in the second quarter [...]
Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
03/08/2026
DEER PARK, Ill., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance
03/08/2026
Second quarter 2026 total global revenue of approximately $240 million, including BRIUMVI U.S. net product revenue of approximately $228 million Raises full year 2026 total global revenue target to approximately $950 [...]
Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome
03/08/2026
Phase 2 clinical study protocol submitted; Small Phase 2 study designed to support regulatory interactions and potential registration upon positive results Ramat Gan, Israel, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Can-Fite [...]
Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease
03/08/2026
Topline six-month efficacy data expected by end of 2027 Phase 3 study follows FDA alignment on registrational trial design through Rare Disease Evidence Principles (RDEP) program Opus Genetics may submit a BLA based on [...]
Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.
03/08/2026
Alignment with FDA on key elements of the study design support planned start of the Phase 2 study in the first quarter of 2027 Long-acting monoclonal antibody TNX-4800 is a rapidly acting alternative to vaccination [...]

Pages